NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide.
Roche broadens obesity drug plans with $1.65B Zealand deal
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to develop its obesity drug candidate.
Zealand and Roche strike $5.3bn obesity treatment deal
The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
BioSpace4d
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
BioWorld1d
Roche, Zealand $5.3B pact focused on amylin analog for obesity
In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Fierce Biotech2d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...